Clinical Trial Update: Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study [Phase 4]

View source ↗

Summary

A randomized crossover Phase 4 study in COPD patients compares triple inhaled therapies Budesonide/Glycopyrronium/Formoterol versus Fluticasone Furoate/Umeclidi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide/Glycopyrronium/Formoterol (budesonide/glycopyrronium/formoterol)
• Trelegy Ellipta (Fluticasone furoate/umeclidinium/vilanterol) (Fluticasone furoate/umeclidinium/vilanterol)

Snippet

Sponsor: Thammasat University | Conditions: COPD, Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Status: COMPLETED